ISYNA1: A Potential Drug Target for Diabetes and Neurological Disorders

Target Name: ISYNA1

NCBI ID: G51477

ISYNA1

ISYNA1: A Potential Drug Target for Diabetes and Neurological Disorders

ISYNA1 (Myo-inositol 1-phosphate synthase) is a protein that is expressed in various tissues, including muscle, heart, and brain. It is a key enzyme in the synthesis of myo-inositol 1-phosphate (IP), which is a crucial molecule in the intracellular signaling pathway known as the insulin/IGF-1 signaling pathway. In recent years, research has identified ISYNA1 as a potential drug target or biomarker for various diseases, including diabetes, heart disease, and neurological disorders.

The insulin/IGF-1 signaling pathway is a critical regulatory network that plays a crucial role in various physiological processes in the body. It is involved in the regulation of glucose metabolism, muscle growth and development, and neurotransmitter synthesis. The pathway is activated by the presence of IP, which is synthesized from its precursor, inositol 1-phosphate (IP3). IP3 is a critical molecule in the pathway because it allows other molecules to interact with the insulin receptor, leading to the activation of the pathway and the start of the signaling cascade.

ISYNA1 is the key enzyme in the synthesis of IP3 from inositol 1-phosphate (IP3). It is a critical enzyme for the production of IP3, which is a key component of the insulin/IGF-1 signaling pathway. ISYNA1 is a protein that is expressed in various tissues, including muscle, heart, and brain. It is a 23-kDa protein that consists of 218 amino acids. It has a molecular weight of 240 kDa and a calculated pI of 6.3.

ISYNA1 is involved in the regulation of various cellular processes in the body. It is involved in the regulation of muscle growth and development, as well as the regulation of neurotransmitter synthesis. It is also involved in the regulation of inflammation and immune responses.

ISYNA1 is a potential drug target or biomarker for various diseases, including diabetes, heart disease, and neurological disorders. Diabetes is a disease that is characterized by the absence of insulin or a lack of effective insulin sensitivity. It is a leading cause of death worldwide, and it is a major contributor to the development of cardiovascular disease. ISYNA1 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism, which are key factors in the development of diabetes.

Heart disease is a condition that is characterized by the development of heart muscle damage or the narrowing of the heart's blood vessels. It is a leading cause of death worldwide, and it is a major contributor to the development of cardiovascular disease. ISYNA1 has been shown to be involved in the regulation of muscle growth and development, as well as the regulation of cardiovascular function.

Neurological disorders are a wide range of conditions that affect the nervous system. They include a variety of conditions, including Parkinson's disease, dystonia, and Huntington's disease. ISYNA1 has been shown to be involved in the regulation of neurotransmitter synthesis, which is a key aspect of neurological function.

In conclusion, ISYNA1 is a protein that is involved in the regulation of various cellular processes in the body. It is a potential drug target or biomarker for various diseases, including diabetes, heart disease, and neurological disorders. Further research is needed to fully understand the role of ISYNA1 in these diseases and to develop effective treatments.

Protein Name: Inositol-3-phosphate Synthase 1

Functions: Key enzyme in myo-inositol biosynthesis pathway that catalyzes the conversion of glucose 6-phosphate to 1-myo-inositol 1-phosphate in a NAD-dependent manner (PubMed:15024000, PubMed:23902760). Rate-limiting enzyme in the synthesis of all inositol-containing compounds (PubMed:15024000)

The "ISYNA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISYNA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets